🧾 What This Document Is

This is a prospectus supplement filed with the SEC. It’s a legal document that provides the specific details for a new bond offering by Danaher Corporation. Think of it as the detailed menu and terms for a big loan the company is taking out. It updates a broader prospectus filed earlier and is required before selling securities to investors.

🏢 What The Company Does

👉 In simple terms, Danaher is a giant science and technology tools company. It owns over 15 operating companies focused on biotech, life sciences, and diagnostics. They sell products and services that are often used repeatedly (like tests, equipment, and consumables) to hospitals, labs, and researchers worldwide. Their famous "Danaher Business System" (DBS) is their playbook for running and improving their businesses efficiently.

💰 The Bond Offering – The Details

Danaher is borrowing €3 billion (euros) by issuing four different types of bonds (notes). Here’s the breakdown:

• €500 million Floating Rate Notes due 2028: Interest rate floats with the market (based on 3-month EURIBOR + 0.38%). Pays interest quarterly.
• €750 million 3.250% Notes due 2030: Fixed 3.25% annual interest, paid yearly.
• €750 million 3.625% Notes due 2034: Fixed 3.625% annual interest, paid yearly.
• €1 billion 4.000% Notes due 2038: Fixed 4.00% annual interest, paid yearly.

👉 Why it matters: The different maturities (2028-2038) and interest structures let Danaher match its borrowing costs to its long-term plans and appeal to different types of investors. The fixed rates lock in their cost of borrowing for decades.

🚀 The Key Move – Funding a Major Acquisition

👉 This is the core reason for the bond sale. Danaher intends to use the €2.98 billion in net proceeds (after fees) to help pay for its planned acquisition of Masimo Corporation, a medical technology company.

🚨 Critical Catch: The bond deal is not conditional on the Masimo acquisition closing. However, if the acquisition falls through or isn't completed by November 16, 2026, Danaher is required to redeem the fixed-rate notes at 101% of their face value. This is a "special mandatory redemption" – a safety net for bondholders.

📦 Financial Impact – What Changes

This offering will significantly increase Danaher's debt.

• As of March 27, 2026, Danaher had ~$18.5 billion in total debt.
• After this offering and a new $5 billion credit facility, its total debt would jump to ~$24.24 billion.

👉 Why it matters: Taking on more debt increases financial leverage. It means higher interest payments and could pressure the company's credit rating. The "Capitalization" table in the filing shows how this deal makes its balance sheet more leveraged.

⚖️ Big Picture: Strengths (👍) and Risks (⚠️)

👍 Strengths:

• Purpose-Driven Debt: The money is earmarked for a strategic acquisition (Masimo) aimed at growing their business.
• Diversified Business: Danaher operates in resilient, long-term growth sectors like healthcare and science.
• Strong Market Position: They have a proven management system (DBS) and a track record of integrating acquisitions.

⚠️ Key Risks:

• Acquisition Risk: The entire plan hinges on closing the Masimo deal. If it fails, the company faces the costly redemption of the fixed-rate notes.
• Currency Risk: All payments are in euros (€). For investors who use other currencies (like US dollars), changes in the EUR/USD exchange rate could erase returns or create gains.
• High Debt Load: The added debt reduces financial flexibility and increases vulnerability to economic downturns or rising interest rates.
• Limited Protections: The bond agreement ("indenture") has few restrictions on Danaher taking on more debt or selling assets.

🔮 What's Next

1. Close the Bond Offering: Expected around April 29, 2026.
2. Close the Masimo Acquisition: The target date is on or before November 16, 2026. This is the critical milestone.
3. Manage Integration: Successfully combine Masimo into Danaher's operations to realize the expected benefits.

👉 For investors, the next major date is the Outside Date for the Masimo deal. Failure to close by then triggers the redemption clause.

🧠 The Analogy

It’s like taking out a construction loan to build a new, ambitious house.
The bond offering is the loan. The Masimo acquisition is the new house. The bank (bondholders) gives you the money, but if you can't get the final building permits (regulatory approval) by a certain date, the loan agreement forces you to buy the loan back from the bank at a premium. Meanwhile, you're on the hook for the loan payments, and the value of the house (and your repayment) depends on the local currency (euros).

🧩 Final Takeaway

Danaher is raising €3 billion in debt to fund a major strategic acquisition. The deal is structured to protect bondholders if the acquisition fails, but it adds significant leverage to Danaher's balance sheet. The success of this move hinges entirely on completing the Masimo purchase and managing the resulting higher debt load.